CISTEM- Heart on chip based on induced pluripotent stem cell technology for personalized medicine

Project aim: CISTEM aims to combine top notch microfluidic technologies and organ-on-a-chip concept, along with the technology of induced pluripotent stem cells, to design a new generation of heart-on-a-chip for the patient treatment.

 

About the project: Many rare diseases cause chronic health problems or are even life-threatening. The impact on the quality of life of affected patients, of whom many are children, is significant. To date, a limited but increasing number of so-called orphan drugs (drugs for rare diseases) are reaching patients. However, most rare diseases are still without any effective treatment. The development of novel human systems for drug discovery therefore represents a major public health priority. Microfluidic technology-based “Organs-on-a-chip” represents a powerful tool for investigating rare disease mechanisms and testing new drug and treatment due to their ability to mimic tailored micro-environment architecture inspired by organ-level functions in vivo. However, due to the variability in rare disease mechanisms from one patient to another, organ on chip technology needs to be more precise and to convey towards personalized medicine. The human-induced pluripotent stem cells (iPSCs) have a strong potential in engineering organ-on-a-chip since they are derived in a patient-matched manner which makes them a superb source to construct human models for personalized drug screening as well as for understanding patient-specific fundamentals of diseases. To provide novel miniaturized platform for investigation of rare diseases able to address the burning issues in precision medicine today, CISTEM is bringing together and synergistically several highly promising research directions which are too often investigated separately at the academic level but also at the industrial level. CISTEM project is implemented by exploiting the complementary expertise of its partners and creating synergies between them through the targeted secondments of staff.